Specialty Pharmacy

Key facts

Federal definition

None; Medicare Part D defines only a cost-based specialty tier

Common accreditors

URAC, ACHC and The Joint Commission

Owners

PBMs, insurers, health systems, retail chains and independents

Distribution models

Open, limited or exclusive networks chosen by manufacturers

What is a specialty pharmacy?

Specialty drugs are usually expensive, may require injection or infusion, cold chain storage or special handling, and often need close monitoring for side effects or adherence. Specialty pharmacies are organized around those needs rather than walk-in retail volume, and many ship medications directly to patients or clinics.

There is no single legal definition of a specialty drug or specialty pharmacy. Payers, pharmacy benefit managers and manufacturers each apply their own criteria, typically combining cost, complexity and the need for patient management.

How specialty pharmacy works

Beyond dispensing, specialty pharmacies typically provide:

• Benefit investigation and prior authorization: staff verify coverage and help prescribers complete payer paperwork.
• Financial assistance: pharmacies connect patients with copay programs, foundations and patient assistance programs.
• Clinical management: pharmacists provide counseling, refill reminders, adherence checks and side effect monitoring.
• Limited distribution: manufacturers may restrict a drug to a small network of specialty pharmacies, for example to support Risk Evaluation and Mitigation Strategy (REMS) requirements, data collection or high-touch services.
• Data reporting: pharmacies in limited networks typically share dispensing and patient status data with the manufacturer under contract.

Why specialty pharmacy matters

Specialty drugs account for a large and growing share of U.S. drug spending, so control of the specialty pharmacy channel matters to manufacturers, payers and investors. Large pharmacy benefit managers own specialty pharmacies and often require members to use them, and the Federal Trade Commission has examined markups on some specialty generic drugs dispensed by PBM-affiliated pharmacies.

For manufacturers, network design is a launch decision: a narrow network improves data visibility and service consistency, while a broad network can widen access. Health systems increasingly run their own specialty pharmacies, which can conflict with payer mandates that steer patients elsewhere. Practices such as white bagging, where a specialty pharmacy ships a clinician-administered drug for a specific patient to the site of care, are also debated.